iTeos and GSK hit enrolment milestone with Phase III TIGIT lung cancer trial
iTeos will receive $35m from GSK as the first patient is dosed in the Phase III trial of the jointly developed monoclonal antibody EOS-448.
iTeos will receive $35m from GSK as the first patient is dosed in the Phase III trial of the jointly developed monoclonal antibody EOS-448.
What's Your Reaction?
